Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06085547 · ClinicalTrials.gov registry record · NA
Rural Tailored COVID-19 Communication to Promote SARS-CoV-2 Antibody Testing in Saliva
A NA study, sponsored by Michigan State University.
- Completed
- Registry status
- NA
- Development phase
- 264
- Enrollment target
NCT06085547: Completed NA study, sponsored by Michigan State University.
NCT06085547 is a NA study that has completed, run by Michigan State University. The registered enrollment target is 264 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06085547, a NA study, has completed, sponsored by Michigan State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 264 participants
- Enrollment target
Study Summary
This study seeks to evaluate communication strategies for better encouraging understanding and uptake of salivary SARS-CoV-2 antibody testing among individuals residing in rural Northern Michigan. This iteration will consider individuals recruited from rural Northern Michigan and assess individuals' willingness to participate in home-based saliva sample collections.
Primary Outcome
Number (percentage) of participants who respond "yes" to be included in the offer to participate in no cost home-based SARS-CoV-2 salivary antibody testing.
Interventions
- BEHAVIORAL General SARS-CoV-2 Communication
- BEHAVIORAL Rural-Targeted SARS-CoV-2 Communication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2023-05-04 |
| Est. Completion | 2023-11-14 |
| Phase | NA |
What the finished NCT06085547 record still lists
NCT06085547 is an interventional study that assigns participants to a tested intervention. The registered 264 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which General SARS-CoV-2 Communication is the first listed.
NCT06085547 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06085547 about?
NCT06085547 is a clinical study titled "Rural Tailored COVID-19 Communication to Promote SARS-CoV-2 Antibody Testing in Saliva". This study seeks to evaluate communication strategies for better encouraging understanding and uptake of salivary SARS-CoV-2 antibody testing among individuals residing in rural Northern Michigan. This iteration will consider individuals recruited from rural Northern Michigan and assess individuals'...
What is the current status of trial NCT06085547?
This trial is currently completed. It is a NA study. The enrollment target is 264 participants. The study started on 2023-05-04. Estimated completion is 2023-11-14.
What interventions are being tested in trial NCT06085547?
The interventions under investigation include: General SARS-CoV-2 Communication (BEHAVIORAL), Rural-Targeted SARS-CoV-2 Communication (BEHAVIORAL).
Who is sponsoring clinical trial NCT06085547?
This trial is sponsored by Michigan State University, which has 120 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06085547's enrollment target sits among peer trials
264 395th of 2000 higher than 1,605 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
- NCT04295863 · 264 participants · Phase 1
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
- NCT05220202 · 264 participants · NA
MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression
- NCT05473013 · 264 participants · NA
Optimizing Digital Health Technology Interventions to Increase Skill Acquisition and Utilization
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI